https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/accelerated-approval-granted-drug-developed-gosh/
Accelerated approval granted for drug developed at GOSH
14 Dec 2016, 9:55 a.m.

The United States Food and Drug Administration (FDA) granted accelerated approval for a new medication to treat Duchenne muscular dystrophy (DMD). The drug, Eteplirsen, was developed by a UK consortium led by Novel Therapies Theme lead, Professor Francesco Muntoni.
DMD is a severe, muscle-wasting condition caused by a fault in a gene, resulting in a failure to produce functional dystrophin. Currently DMD has few treatment options.
Eteplirsen was filed by Sarepta Therapeutics for accelerated approval by the FDA and is planned for immediate clinical use in the US. The approval for use in the EU is still underway. The drug will be used to treat patients with a specific subset of mutations of the dystrophin gene that affects around 13% of boys with DMD.
The drug ‘skips’ a part of the gene that makes dystrophin, which results in a shortened form of the dystrophin protein being produced, alleviating some of the symptoms of DMD and potentially extending a patient's mobility for a longer period of time.

New study pinpoints why some transplanted kidneys are rejected
Researchers at University College London (UCL), the Wellcome Sanger Institute and the University of Cambridge combined technology that determines the genetic or RNA sequence of individual cells with powerful 3D imaging to look at lymphatic vessels

Teenager off to university after life-changing gene therapy
A teenager with a rare, life-limiting genetic condition is off to university after receiving a gene therapy that changed his life.

Toddler doing well after receiving newest gene therapy available on NHS
A toddler with a life-limiting and life-threatening rare disease is the youngest to be treated with the newest gene therapy available on the NHS at GOSH.

Join us in the countdown to Rare Disease Day 2025
Rare Disease Day takes place annually on the last day of February and is a global opportunity to increase awareness and advocate for those living with rare conditions.